Compare IPCA Labs with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUN PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUN PHARMA IPCA LABS/
SUN PHARMA
 
P/E (TTM) x 23.6 79.4 29.7% View Chart
P/BV x 8.4 3.4 248.8% View Chart
Dividend Yield % 0.1 0.6 22.9%  

Financials

 IPCA LABS   SUN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
SUN PHARMA
Mar-20
IPCA LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,042484 215.2%   
Low Rs590315 187.2%   
Sales per share (Unadj.) Rs298.6136.9 218.2%  
Earnings per share (Unadj.) Rs35.017.5 200.6%  
Cash flow per share (Unadj.) Rs49.426.0 190.1%  
Dividends per share (Unadj.) Rs3.004.00 75.0%  
Dividend yield (eoy) %0.41.0 36.7%  
Book value per share (Unadj.) Rs247.1188.7 131.0%  
Shares outstanding (eoy) m126.352,399.26 5.3%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.72.9 93.6%   
Avg P/E ratio x23.322.9 101.8%  
P/CF ratio (eoy) x16.515.4 107.4%  
Price / Book Value ratio x3.32.1 155.9%  
Dividend payout %8.622.9 37.4%   
Avg Mkt Cap Rs m103,108958,864 10.8%   
No. of employees `00013.417.8 75.7%   
Total wages/salary Rs m7,87463,624 12.4%   
Avg. sales/employee Rs Th2,807.018,490.6 15.2%   
Avg. wages/employee Rs Th585.83,582.6 16.4%   
Avg. net profit/employee Rs Th329.02,357.6 14.0%   
INCOME DATA
Net Sales Rs m37,732328,375 11.5%  
Other income Rs m5776,360 9.1%   
Total revenues Rs m38,309334,735 11.4%   
Gross profit Rs m6,90169,898 9.9%  
Depreciation Rs m1,82420,528 8.9%   
Interest Rs m1893,027 6.2%   
Profit before tax Rs m5,46552,702 10.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m1,0428,228 12.7%   
Profit after tax Rs m4,42241,868 10.6%  
Gross profit margin %18.321.3 85.9%  
Effective tax rate %19.115.6 122.2%   
Net profit margin %11.712.8 91.9%  
BALANCE SHEET DATA
Current assets Rs m23,778316,542 7.5%   
Current liabilities Rs m10,975157,064 7.0%   
Net working cap to sales %33.948.6 69.9%  
Current ratio x2.22.0 107.5%  
Inventory Days Days10488 118.5%  
Debtors Days Days66105 63.0%  
Net fixed assets Rs m20,368243,102 8.4%   
Share capital Rs m2532,399 10.5%   
"Free" reserves Rs m30,971450,245 6.9%   
Net worth Rs m31,224452,645 6.9%   
Long term debt Rs m1,40920,289 6.9%   
Total assets Rs m45,507682,525 6.7%  
Interest coverage x30.018.4 162.7%   
Debt to equity ratio x00 100.6%  
Sales to assets ratio x0.80.5 172.3%   
Return on assets %10.16.6 154.0%  
Return on equity %14.29.2 153.1%  
Return on capital %17.311.2 154.2%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30874,219 23.3%   
Fx outflow Rs m6,26627,964 22.4%   
Net fx Rs m11,04246,255 23.9%   
CASH FLOW
From Operations Rs m4,92365,548 7.5%  
From Investments Rs m-1,563-25,888 6.0%  
From Financial Activity Rs m-1,832-57,151 3.2%  
Net Cashflow Rs m1,528-13,857 -11.0%  

Share Holding

Indian Promoters % 45.9 63.7 72.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.1 222.2%  
FIIs % 25.3 23.0 110.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.3 209.6%  
Shareholders   36,892 133,026 27.7%  
Pledged promoter(s) holding % 2.1 0.5 403.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  WOCKHARDT  VENUS REMEDIES  STRIDES PHARMA SCIENCE  GLENMARK PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 9, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS